Keros Therapeutics’ (KROS) Neutral Rating Reaffirmed at Guggenheim

Keros Therapeutics (NASDAQ:KROS)‘s stock had its “neutral” rating restated by analysts at Guggenheim in a research report issued to clients and investors on Friday,Benzinga reports.

KROS has been the topic of several other research reports. BTIG Research cut Keros Therapeutics from a “buy” rating to a “neutral” rating in a research report on Thursday, December 12th. Wedbush restated an “outperform” rating and set a $84.00 price objective on shares of Keros Therapeutics in a research report on Thursday, November 7th. Oppenheimer dropped their target price on shares of Keros Therapeutics from $63.00 to $23.00 and set an “outperform” rating for the company in a research report on Thursday. Truist Financial reduced their price target on shares of Keros Therapeutics from $100.00 to $43.00 and set a “buy” rating for the company in a research note on Monday, December 23rd. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Keros Therapeutics in a research report on Friday, November 22nd. Four research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat.com, Keros Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $70.22.

Keros Therapeutics Stock Performance

Shares of KROS opened at $11.51 on Friday. The stock has a fifty day moving average of $38.65 and a 200-day moving average of $47.61. Keros Therapeutics has a 52 week low of $9.77 and a 52 week high of $73.00. The stock has a market capitalization of $466.43 million, a price-to-earnings ratio of -2.20 and a beta of 1.43.

Keros Therapeutics (NASDAQ:KROS) last released its earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.28) by ($0.13). The firm had revenue of $0.39 million during the quarter. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The firm’s revenue for the quarter was up 4750.0% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.33) EPS. As a group, equities analysts forecast that Keros Therapeutics will post -4.74 EPS for the current year.

Hedge Funds Weigh In On Keros Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Geode Capital Management LLC boosted its stake in Keros Therapeutics by 6.8% during the third quarter. Geode Capital Management LLC now owns 725,621 shares of the company’s stock worth $42,146,000 after buying an additional 46,041 shares during the last quarter. Barclays PLC increased its holdings in Keros Therapeutics by 140.1% in the third quarter. Barclays PLC now owns 60,014 shares of the company’s stock valued at $3,484,000 after buying an additional 35,022 shares during the last quarter. Wellington Management Group LLP acquired a new position in Keros Therapeutics in the third quarter valued at $868,000. Point72 DIFC Ltd grew its holdings in shares of Keros Therapeutics by 9.8% during the third quarter. Point72 DIFC Ltd now owns 19,255 shares of the company’s stock worth $1,118,000 after buying an additional 1,715 shares during the last quarter. Finally, Point72 Asset Management L.P. boosted its holdings in shares of Keros Therapeutics by 155.9% in the third quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company’s stock valued at $55,025,000 after acquiring an additional 577,220 shares in the last quarter. 71.56% of the stock is currently owned by institutional investors and hedge funds.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.